COVID-19, Patents and the Never-Ending Tension between Proprietary Rights and the Protection of Public Health

Bonadio, Enrico; Baldini, Andrea

doi:10.1017/err.2020.24

Cited by 16 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chinese were first to evaluate the effectiveness of remdesivir, chloroquine and Kaletra in treating COVID-19 patients [25,136]. However, simultaneous intentions for patent applications raised global concerns [242]. This led to a sort of conflict between Chinese institutes and the pharmaceutical companies having original patents for the drugs [242].…”

Section: Patents On Successful Methodologies On Various Aspects Of Comentioning

confidence: 99%

“…However, simultaneous intentions for patent applications raised global concerns [242]. This led to a sort of conflict between Chinese institutes and the pharmaceutical companies having original patents for the drugs [242]. Thus, avoiding such differences and focusing on improving the health of people in times of pandemic need to be the priority rather than personnel monetary gains [242].…”

Section: Patents On Successful Methodologies On Various Aspects Of Comentioning

confidence: 99%

“…They are patented for use against viruses (Ebola), malaria and HIV/AIDS, respectively, however, have shown potential for application in COVID-19 hence being evaluated in clinical trials ( https://ttconsultants.com/blog/potential-covid-19-drugs-and-their-patents-in-major-jurisdictions/ ). Wuhan Institute of Virology in China has filed a patent for the application of remdesivir in COVID-19 [ 240 ] and Suzhou-based BrightGene Bio-Medical Technology for the synthesis of its active ingredient [ 241 , 242 ]. Chinese were first to evaluate the effectiveness of remdesivir, chloroquine and Kaletra in treating COVID-19 patients [ 25 , 136 ].…”

Section: Patents On Successful Methodologies On Various Aspects Of Comentioning

confidence: 99%

See 2 more Smart Citations

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Rabaan

Al-Ahmed

Sah

et al. 2020

Ann Clin Microbiol Antimicrob

109

View full text Add to dashboard Cite

A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.

show abstract

Section: Patents On Successful Methodologies On Various Aspects Of Comentioning

confidence: 99%

Section: Patents On Successful Methodologies On Various Aspects Of Comentioning

confidence: 99%

Section: Patents On Successful Methodologies On Various Aspects Of Comentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Rabaan

Al-Ahmed

Sah

et al. 2020

Ann Clin Microbiol Antimicrob

109

View full text Add to dashboard Cite

show abstract

“…Due to the crisis caused by AIDS and HIV virus, the Government of the Republic of South Africa passed a law that determined a reduction of prices of medicines used for the treatment of this illness in order to make them more accessible. Even though this action caused dissatisfaction among pharmaceutical companies and legal procedures, such restrictions in cases of pandemics seem like an adequate compromising solution [19].…”

Section: Interfunctional Dependence Of Patents and Medicinementioning

confidence: 99%

The SARS-COV-2 pandemic and the challenges of intellectual property rights

Lukinović

Vitošević²

2021

Srp Arh Celok Lek

View full text Add to dashboard Cite

The COVID-19 virus pandemic had a drastic impact on the social lives of billions of people, hitting certain industries like a hurricane. What the answer will be to this and possible other occurrences of pandemics in the future will largely depend on the inventiveness of the researchers. Intellectual property is the first system to offer answers, opening patent bases to anyone developing new technologies to fight the COVID-19 pandemic. The need for the means of prevention, treatment, and care has caused thousands of different researches, which find inspiration and guidance for discovering new solutions in patents that already exist. Publication of scientific papers has never been so intense in any scientific field as in medicine since the fight against this virus began. The time since the beginning of the virus pandemic has shown that science and innovators are ready for such challenges, but the global health crisis has imposed a new challenge on the intellectual property system, which refers to the strict implementation of its rights at times when rapid and global effect is needed in order to avoid additional deterioration due to further circulation of the virus among the population, which inevitably leads to the emergence of new strains of the virus.

show abstract

“…But the situation has changed radically in the shadow of COVID-19. Instead of tracking for multiple purposes, tracking occurs to meet one public healthcentred purpose: to monitor the rate of change in a community (Bonadio and Baldini, 2020). Because this is a public health emergency, cellphone data is considered fair game for mass tracking since it is not for marketing goods.…”

Section: The Emergence Of the Data Shimmermentioning

confidence: 99%

Doing nothing does something: Embodiment and data in the COVID-19 pandemic

Vallee

2020

Big Data & Society

View full text Add to dashboard Cite

The COVID-19 pandemic redefines how we think about the body, physiologically and socially. But what does it mean to have and to be a body in the COVID-19 pandemic? The COVID-19 pandemic offers data scholars the unique opportunity, and perhaps obligation, to revisit and reinvent the fundamental concepts of our mediated experiences. The article critiques the data double, a longstanding concept in critical data and media studies, as incompatible with the current public health and social distancing imperative. The data double, instead, is now the presupposition of a new data entity, which will emerge out of a current data shimmer: a long-sustaining transition that blurs the older boundaries of bodies and the social, and establishes new ethical boundaries around the (in)activity and (im)mobility of doing nothing to do something. The data double faces a unique dynamic in the COVID-19 pandemic between boredom and exhaustion. Following the currently simple rule to stay home presents data scholars the opportunity to revisit the meaning of data as something given, a shimmering embodied relationship with data that contributes to the common good in a global health crisis.

show abstract

COVID-19, Patents and the Never-Ending Tension between Proprietary Rights and the Protection of Public Health

Cited by 16 publications

References 5 publications

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

The SARS-COV-2 pandemic and the challenges of intellectual property rights

Doing nothing does something: Embodiment and data in the COVID-19 pandemic

Contact Info

Product

Resources

About